Spravato, IV ketamine and at-home ketamine compared plainly

Three different things are sold under nearly the same word, and telling them apart is the most useful piece of knowledge a patient can carry into this category.

The confusion is not the patient's fault. We asked 443 adults about Spravato, and 73 percent of them had never once heard the name. The word was familiar to another 21 percent, though they had no idea what the drug did; only 6 percent could describe it. When almost nobody starts with a working definition, marketing gets to write one.

Below is the comparison, on the points that change your experience: what it is, who supervises, what the government approved it for, and what it costs in time and money.

Option one: esketamine nasal spray, brand name Spravato

What it is: esketamine in a nasal spray, prescribed together with an antidepressant you swallow.

Regulatory standing: federal regulators signed off on it for adult depression that two or more earlier drugs failed to shift, plus a second use during acute suicidal crises in adult major depression. A restricted program controls where it goes.

Where it happens: a certified clinic. You use the device under a clinician's eye, remain on site for monitoring, and someone else drives you home.

Time cost: high and recurring. Sessions follow a set course, and each one eats a good part of the day once you add travel, monitoring, and the ride.

Money: billed through regular health care channels. Insurance may pay, which usually also means prior authorization and proof of earlier medication trials.

If you want to see how a clinic running this model describes the visits, Brain Recovery Centers publishes an explanation of its Spravato treatment.

Option two: intravenous ketamine in a clinic

What it is: generic ketamine, a decades-old anesthetic, infused at low doses for mood conditions.

Regulatory standing: off label. The drug has FDA approval, but not for this use. Using a drug off label is legal and routine in medicine; it also means no agency sets the dose, the spacing, or the setting, and clinics differ more than patients expect.

Where it happens: infusion clinics run by anesthesiologists, psychiatrists, or other clinicians. Monitoring standards vary, so ask rather than assume.

Time cost: similar per visit to the spray, and you still need a ride.

Money: often self-pay, since off-label use complicates coverage. Ask for the price of a whole course, not one infusion.

Option three: ketamine prescribed for use at home

What it is: usually a lozenge, prescribed after a video evaluation and mailed to you.

Regulatory standing: off label, with dosing done while nobody is present. The model spread fast under loosened telehealth rules and has drawn scrutiny from regulators and professional groups.

Where it happens: your home, alone, which is both the selling point and the worry. Nobody checks your blood pressure, and nobody is there if a session goes badly.

Time cost: by far the lowest. Money: usually a subscription or package that you pay.

How our respondents said they would choose

Survey preferences did not simply follow convenience. On delivery, 44 percent of respondents picked a clinic visit in person. Video visits from home drew 22 percent, a start-in-clinic, move-home-later plan 23 percent, and 11 percent did not lean either way.

Combined, 67 percent wanted clinic involvement at least early on, which fits what they said about trust. FDA approval was the deciding factor for 19 percent and a big factor for 40 percent, together 59 percent of the sample. It mattered somewhat to 27 percent and was irrelevant to 14 percent.

Coverage pointed the same way. Offered insured care with added steps or quicker care paid out of pocket, half of those we asked, 51 percent, took the insured option. Under a quarter, 23 percent, chose to pay for speed, and the remaining 26 percent could not choose. A model that lives outside insurance is asking half the market to go against its stated preference.

The fourth option people rarely weigh

Not every alternative is a drug. Transcranial magnetic stimulation, or TMS, is a device-based depression treatment with no medication, and it belongs on the list.

Our respondents knew little about it. Half had never heard of TMS but still valued the absence of medication. Another 25 percent were in the dark about it and shrugged at the drug-free part. Among those who did know it, 13 percent put heavy weight on its being drug-free and 12 percent said that barely moved them.

Roughly one in four had heard of the treatment, while nearly two thirds cared about the very feature it offers. That is a preference with no information attached, which describes this whole market.

Questions that separate the three in a single phone call

• "Is this the FDA-approved esketamine spray, or ketamine used off label?"
• "Is your site certified under the restricted program?"
• "Who is in the room during a session, and what do you monitor?"
• "Will you want records of my earlier antidepressant trials?"
• "Do you bill insurance, and what would a complete course cost me?"
• "Who handles my psychiatric care long term, and will you work with my current prescriber?"

A clinic that answers all six crisply is telling you something useful about how it runs. So is one that will not.

What a comparison cannot do

This is a map, not a recommendation. Which option fits, if any, depends on your diagnosis, medical history, other medications, blood pressure, history with substances, and circumstances. A clinician who can review your record makes that call, and no article should pretend otherwise.

What you can take from here is the vocabulary. Knowing these are three separate arrangements lets you ask a real question instead of accepting whichever version is in front of you.

If depression has led you toward thoughts of suicide, act on it today instead of waiting for a visit. Nationwide, the number 988 puts you through to the Lifeline by phone or by text message, free, confidential, day and night.

Methodology

We, the publisher, commissioned the survey behind these figures and covered its cost. Through the Pollfish consumer panel it reached 443 consenting adults between 18 and 64, spread over ten Midwest states, and stopped taking responses on June 23, 2026. Multi-select answers appear as the share of respondents choosing each one, so they add to more than 100. Pollfish has completed final panel validation, and each figure here is taken from it.